Medpace (NASDAQ:MEDP) CEO August Troendle Sells 23,862 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 23,862 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $592.07, for a total value of $14,127,974.34. Following the sale, the chief executive officer directly owned 862,315 shares in the company, valued at approximately $510,550,842.05. This trade represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Medpace Price Performance

MEDP stock traded down $6.02 during midday trading on Thursday, reaching $586.16. The company had a trading volume of 137,221 shares, compared to its average volume of 412,888. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $625.00. The stock has a 50 day moving average price of $545.66 and a 200-day moving average price of $429.61. The company has a market capitalization of $16.51 billion, a price-to-earnings ratio of 40.99, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period last year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. William Blair restated a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Rothschild & Co Redburn downgraded Medpace from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Deutsche Bank Aktiengesellschaft lifted their target price on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Finally, Rothschild Redb cut Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the company. According to MarketBeat, Medpace presently has an average rating of “Hold” and an average target price of $487.18.

Hedge Funds Weigh In On Medpace

Hedge funds and other institutional investors have recently modified their holdings of the business. Quent Capital LLC purchased a new stake in shares of Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. bought a new position in Medpace in the 3rd quarter valued at $27,000. Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter valued at $35,000. Root Financial Partners LLC bought a new stake in shares of Medpace during the 3rd quarter worth $38,000. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.